DK0628074T3 - In vitro aktivering af cytotoksiske T-celler. - Google Patents

In vitro aktivering af cytotoksiske T-celler.

Info

Publication number
DK0628074T3
DK0628074T3 DK93906141T DK93906141T DK0628074T3 DK 0628074 T3 DK0628074 T3 DK 0628074T3 DK 93906141 T DK93906141 T DK 93906141T DK 93906141 T DK93906141 T DK 93906141T DK 0628074 T3 DK0628074 T3 DK 0628074T3
Authority
DK
Denmark
Prior art keywords
cytotoxic
cells
autoimmune
class
relates
Prior art date
Application number
DK93906141T
Other languages
Danish (da)
English (en)
Inventor
Michael Jackson
Pierre Langlade-Demoyen
Per A Peterson
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of DK0628074T3 publication Critical patent/DK0628074T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0601—Invertebrate cells or tissues, e.g. insect cells; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/75—Vector systems having a special element relevant for transcription from invertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK93906141T 1992-02-19 1993-02-18 In vitro aktivering af cytotoksiske T-celler. DK0628074T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/841,662 US5314813A (en) 1992-02-19 1992-02-19 Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines
PCT/US1993/001557 WO1993017095A1 (en) 1992-02-19 1993-02-18 In vitro activation of cytotoxic t cells

Publications (1)

Publication Number Publication Date
DK0628074T3 true DK0628074T3 (da) 2003-04-22

Family

ID=25285417

Family Applications (2)

Application Number Title Priority Date Filing Date
DK93906141T DK0628074T3 (da) 1992-02-19 1993-02-18 In vitro aktivering af cytotoksiske T-celler.
DK02014141T DK1249490T3 (da) 1992-02-19 1993-02-18 In vitro aktivering af cytotoksiske T-celler

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK02014141T DK1249490T3 (da) 1992-02-19 1993-02-18 In vitro aktivering af cytotoksiske T-celler

Country Status (10)

Country Link
US (3) US5314813A (de)
EP (2) EP1249490B1 (de)
JP (2) JP3739786B2 (de)
AT (2) ATE338815T1 (de)
AU (1) AU3728193A (de)
DE (2) DE69332606T2 (de)
DK (2) DK0628074T3 (de)
ES (2) ES2272611T3 (de)
PT (1) PT1249490E (de)
WO (1) WO1993017095A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US5583031A (en) * 1992-02-06 1996-12-10 President And Fellows Of Harvard College Empty major histocompatibility class II heterodimers
CA2069541C (en) * 1992-05-26 2005-02-01 Cornelis J. M. Melief Induction of an antigen-specific t-lymphocyte response
WO1994003205A1 (en) * 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
US5571669A (en) * 1993-01-14 1996-11-05 The University Of Pennsylvania Transcription and nucleic acid sequence determination with short primer DNA/RNA molecules and RNA polymerase
EP0726941B1 (de) * 1993-08-06 2002-04-03 Epimmune Inc. Methoden zur (ex vivo) therapie mittels peptid - bestueckten antigen - praesentierenden zellen zur aktivierung von ctl
FR2710536B1 (fr) * 1993-09-29 1995-12-22 Transgene Sa Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire.
US6090587A (en) * 1993-10-25 2000-07-18 Corixa Corporation Prokaryotic expression of MHC proteins
FR2722207B1 (fr) * 1994-07-07 1996-09-27 Inst Nat Sante Rech Med Methode pour generer une population de cellules presentant a leur surface une forte densite d'un pepride exogene specifique associe azx molecules du cmh; population de cellules
US5674681A (en) 1994-12-06 1997-10-07 Rothenberg; Barry E. Methods to identify hemochromatosis
CA2214649C (en) * 1995-03-08 2007-06-12 Zeling Cai Antigen presenting system and methods for activation of t-cells
US5576197A (en) * 1995-04-07 1996-11-19 Molecular Bio-Products Polymerase chain reaction container and methods of using the same
US5794221A (en) * 1995-07-07 1998-08-11 Egendorf; Andrew Internet billing method
CA2243235C (en) * 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
NZ331688A (en) 1996-03-28 2000-02-28 Univ Johns Hopkins Soluble divalent and multivalent heterodimeric analogs of proteins
ES2278390T3 (es) * 1996-05-23 2007-08-01 The Scripps Research Institute Sistema de presentacion de antigenos de clase ii de cmh y procedimientos de activacion de linfocitos t cd4+.
US20050003431A1 (en) * 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
DE69737028T2 (de) * 1996-09-06 2007-06-28 Ortho-Mcneil Pharmaceutical, Inc. Reinigung von antigenspezifischen t-zellen
US20020151690A1 (en) * 1997-08-12 2002-10-17 Luxemburg Alain T Purification of antigen-specific t cells
US7556805B2 (en) * 1996-12-10 2009-07-07 Sloan-Kettering Inststute for Cancer Research and The Animal Medical Center Compositions for treatment of melanoma and method of using same
US6328969B1 (en) 1996-12-10 2001-12-11 Sloan-Kettering Institute For Cancer Research Method and compositions for stimulation of an immune response to a differentiation antigen stimulated by an altered differentiation antigen
US20100068262A1 (en) * 1997-02-18 2010-03-18 Sloan-Kettering Institute For Cancer Research Method and Compositions for Stimulation of an Immune Response to PSMA using a Xenogeneic PSMA Antigen
US20100068263A1 (en) * 1997-02-18 2010-03-18 Sloan-Kettering Institute For Cancer Research Method and Compositions for Stimulation of an Immune Response to TRP2 using a Xenogeneic TRP2 Antigen
US20020164318A1 (en) * 1997-02-18 2002-11-07 Houghton Alan N. Cell lines and vectors for stimulation of an immune response to a differentiation antigen stimulated by an altered antigen
US8021666B2 (en) * 1997-02-18 2011-09-20 Sloan-Kettering Institute For Cancer Research Method and compositions for stimulation of an immune response to CD20 using a xenogeneic CD20 antigen
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
US6713250B1 (en) 1997-08-08 2004-03-30 The Research Foundation Of State University Of New York Identification of human allergens and T-lymphocyte antigens in vitro
JP4789294B2 (ja) * 1997-08-22 2011-10-12 ソレクサ・インコーポレイテッド ローリングプライマーを用いたｄｎａ伸長および分析
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6153398A (en) * 1997-12-24 2000-11-28 The University Of Chicago Method to identify specific inhibitors of IMP dehydrogenase
JP2002506832A (ja) * 1998-03-20 2002-03-05 ジェンザイム・コーポレーション 抗癌免疫応答を誘導する方法
US6682741B1 (en) * 1998-06-10 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services β2 microglobulin fusion proteins and high affinity variants
EP1086224B1 (de) * 1998-06-10 2006-03-29 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES B2microglobulin fusionsproteine und varianten mit hoher affinität
CA2343313A1 (en) * 1998-09-14 2000-03-23 Lars Ostergaard Pedersen A method of producing a functional immunoglobulin superfamily protein
HK1041312B (en) * 1999-04-16 2006-09-29 Ortho-Mcneil Pharmaceutical, Inc. Method for the detection of antigen specific t-cells
NZ516237A (en) * 1999-05-25 2004-03-26 Human Genome Sciences Inc Meth1 and meth2 polynucleotides and polypeptides
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US7541184B2 (en) * 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US20070026433A1 (en) 2001-03-09 2007-02-01 Hildebrand William H Epitope testing using soluble HLA
ES2643582T3 (es) * 2001-02-20 2017-11-23 Janssen Pharmaceuticals, Inc. Antígeno de Drosophila artificial que presenta célula para preparar suspensión de células CD8 para su uso en el tratamiento del cáncer
AU2008200524B2 (en) * 2001-02-20 2012-01-12 Ortho-Mcneil Pharmaceutical, Inc. A cell therapy method for the treatment of tumors
US20040071671A1 (en) * 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
US7811816B2 (en) * 2001-05-15 2010-10-12 Ortho-Mcneil Pharmaeutical, Inc. Isolated CD8 +T lymphocytes specifically cytotoxic for a disease causing target cell
US7745140B2 (en) * 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
WO2003057171A2 (en) * 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
US7638326B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
WO2010011999A2 (en) 2008-07-25 2010-01-28 The Regents Of The University Of California Methods and compositions for eliciting an amyloid-selective immune response
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
WO2005118788A2 (en) 2004-05-27 2005-12-15 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
JP5543207B2 (ja) * 2006-10-04 2014-07-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 不活性化された人工抗原提示細胞の調製および細胞治療におけるそれらの使用
RU2559782C2 (ru) 2007-12-17 2015-08-10 Марфл Аб Набор для детекции спор, происходящих из микобактерий
US8467973B2 (en) * 2009-07-28 2013-06-18 Promising Future, Llc Pairing processes for preparing alloreactive cytotoxic T cells
US10857219B2 (en) 2014-03-28 2020-12-08 The Board Of Regents Of The University Of Oklahoma Compositions comprising soluble HLA/M. tuberculosis-specific ligand complexes and methods of production and use thereof
EP3377650A1 (de) * 2015-11-19 2018-09-26 Susanne Wagner Signaturen zur vorhersage der krebsimmuntherapiereaktion

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2096650T3 (es) * 1990-05-10 1997-03-16 Dana Farber Cancer Inst Inc Mejora de la asociacion de peptidos exogenos con moleculas de la clase i del mhc en celulas del sistema inmunitario.
NO175188C (no) * 1990-06-27 1994-09-14 Sjur Olsnes Fremgangsmåte for fremstilling av et peptidkonjugat med evne til å trenge inn i cellecytosol

Also Published As

Publication number Publication date
EP1249490A2 (de) 2002-10-16
US5529921A (en) 1996-06-25
EP0628074B1 (de) 2003-01-02
US5827737A (en) 1998-10-27
EP1249490B1 (de) 2006-09-06
AU3728193A (en) 1993-09-13
ES2272611T3 (es) 2007-05-01
PT1249490E (pt) 2007-01-31
DE69334062T2 (de) 2007-03-15
ATE338815T1 (de) 2006-09-15
JPH07504089A (ja) 1995-05-11
ATE230435T1 (de) 2003-01-15
DE69332606D1 (de) 2003-02-06
EP0628074A1 (de) 1994-12-14
JP2006022111A (ja) 2006-01-26
ES2190432T3 (es) 2003-08-01
EP0628074A4 (de) 1999-01-20
EP1249490A3 (de) 2003-03-05
JP3739786B2 (ja) 2006-01-25
DE69334062D1 (de) 2006-10-19
DE69332606T2 (de) 2003-10-23
DK1249490T3 (da) 2007-01-08
US5314813A (en) 1994-05-24
JP4584794B2 (ja) 2010-11-24
WO1993017095A1 (en) 1993-09-02

Similar Documents

Publication Publication Date Title
DK1249490T3 (da) In vitro aktivering af cytotoksiske T-celler
EP0690915A4 (de) Für den vorläufer des für die tumorabstossung verantwortlichen antigens mage-3 kodierendes, isoliertes nukleinsäuremolekül und seine verwendung
ATE165010T1 (de) Menschliches ifn-beta2/il-6, dessen reinigung und verwendungen
ZA944196B (en) Isolated peptides which form complexes with MHC molecule HLA-C-clone 10 and uses thereof
NZ226005A (en) Covalent conjugates of a human cytokine and a human immunoglobulin, processes for their manufacture and pharmaceutical compositions thereof
ES2156852T3 (es) Citoquina mamifera, il-11.
ES2104565T3 (es) Determinantes anti-receptor de celulas t como tratamiento de enfermedades autoinmunes.
GR1005153B (el) Πρωτεινες συντηξεως, παρασκευη τους και χρηση τους.
ES8400770A1 (es) Un metodo para producir una molecula de adn recombinante caracterizada por una secuencia de adn codificada de un coni- peptido semejante al, interferon humano.
ATE209680T1 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
ES8506347A1 (es) Un metodo para producir un polipeptido de tipo il-2-".
HUP0000318A2 (hu) Tumorvakcina és eljárás előállítására
ATE183195T1 (de) Isolierte, von mage-3 abgeleitete peptide, welche mit hla-a2 molekülen komplexieren
EP0365525A4 (en) Lymphocyte inhibition by hla peptides
DE3853842D1 (de) Wachstumsregler zusammenhängend mit Blutplättchen.
ATE309382T1 (de) Rekombinante adenovirenvektoren zur gentherapie der menschlichen krebse
CY1105029T1 (el) Μεθοδοι και συνθεσεις για θεραπειες καρκινου χρησιμοποιωντας γονιδια που κωδικοποιουν εκκρινομενες πρωτεϊνες οπως ιντερφερονη-βητα
CA2095335A1 (en) Cell growth inhibitors
ES2145061T3 (es) Diagnostico y terapia a base de peptidos para el tratamiento de las espondiloartropatias.
NO864986L (no) Rekombinant resintoksin.
HK105091A (en) Photosynthesis in men's blood to cure cancer-part 2 phmd(cancer)
HK53791A (en) Po-man's photosynthesis in men's blood to cure cancer (phmdcc)
GEP19970665B (en) Processes for producing human interferon-like polypeptides
ES1001298U (es) Diadema
UA66753C2 (en) Immunostimulator and method for its production